JAKAVI

Reason for request

Clinical Benefit

Substantial

The actual benefit of JAKAVI is substantial in the Marketing Authorisation indication.

Clinical Added Value

moderate

In view of the established efficacy on reducing splenic volume and the symptoms resulting from this, the Committee considers that JAKAVI provides a moderate improvement in actual benefit (level III) in the management of patients suffering from primary myelofibrosis or myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia.